Publications by authors named "Karl D Lewis"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

372

Total Likes

3

Extended Reach

22,165

Social Features

5
I
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
Danny Rischin, Nikhil I Khushalani, Chrysalyne D Schmults, Alexander Guminski, Anne Lynn S Chang, Karl D Lewis, Annette M Lim, Leonel Hernandez-Aya, Brett G M Hughes, Dirk Schadendorf

J Immunother Cancer· August 2021

Videos about Article: user

1 4 2

View All Article and Social Media Activity
A
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Brett G M Hughes, Alexander Guminski, Samantha Bowyer, Michael R Migden, Chrysalyne D Schmults, Karl D Lewis

J Am Acad Dermatol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.
Jacqueline A Turner, Robert J Van Gulick, William A Robinson, Tariq Mughal, Richard P Tobin, Karl D Lewis

Int J Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1).
Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, Seth D Rosen, Christoper J Hoimes, Karl D Lewis

J Immunother Cancer· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life in cemiplimab-treated patients with locally advanced basal cell carcinoma in a Phase II clinical trial.
Alexander J Stratigos, Chieh-I Chen, Cristina Ivanescu, Karl D Lewis, Ketty Peris

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
Omid Hamid, Karl D Lewis, Amy Weise, Meredith McKean, Kyriakos P Papadopoulos

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with metastatic basal cell carcinoma treated with cemiplimab: Analysis of a phase 2 trial.
Ketty Peris, Timothy J Inocencio, Alexander J Stratigos, Karl D Lewis, Zeynep Eroglu

Cancer Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Alain P Algazi, James Moon, Christopher D Lao, Bartosz Chmielowski, Kari L Kendra, Karl D Lewis

Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
Alexander J Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Karl D Lewis

J Am Acad Dermatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma.
Richard P Tobin, Dasha T Cogswell, Victoria M Cates, Dana M Davis, Jessica S W Borgers, Karl D Lewis

Clin Cancer Res· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.
Joseph M Unger, Amy Darke, Megan Othus, Thach-Giao Truong, Nikhil Khushalani, Karl D Lewis

JAMA Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Jason Chesney, Karl D Lewis, Harriet Kluger, Omid Hamid, Eric Whitman

J Immunother Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting wild-type TP53 using AMG 232 in combination with MAPK inhibition in Metastatic Melanoma; a phase 1 study.
Stergios J Moschos, Shahneen Sandhu, Karl D Lewis, Ryan J Sullivan, Igor Puzanov

Invest New Drugs· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.
Kenneth F Grossmann, Megan Othus, Sapna P Patel, Ahmad A Tarhini, Vernon K Sondak, Karl D Lewis

Cancer Discov· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Alexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, Dirk Schadendorf, Genevieve Boland, Karl D Lewis

Future Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection.
Robert J Torphy, Chloe Friedman, Felix Ho, Laura D Leonard, Daniel Thieu, Karl D Lewis

Ann Surg Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again.
Christina M Davis, Karl D Lewis

Ther Adv Med Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Craig L Slingluff, Karl D Lewis, Robert Andtbacka, John Hyngstrom, Mohammed Milhem

J Immunother Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Adi Diab, Scott S Tykodi, Gregory A Daniels, Michele Maio, Brendan D Curti, Karl D Lewis

J Clin Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Amod A Sarnaik, Omid Hamid, Nikhil I Khushalani, Karl D Lewis, Theresa Medina

J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors.
Jessica S W Borgers, Richard P Tobin, Robert J Torphy, Victoria M Vorwald, Robert J Van Gulick, Karl D Lewis

J Natl Compr Canc Netw· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.
Alexander J Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Karl D Lewis

Lancet Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitor therapy in HIV-associated Merkel cell carcinoma: A case series of 3 patients.
Song Y Park, Candice Church, Nora A Alexander, Michi M Shinohara, Kelly G Paulson, Karl D Lewis

JAAD Case Rep· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
Paolo A Ascierto, Antoni Ribas, James Larkin, Grant A McArthur, Karl D Lewis

J Transl Med· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.
Carol M Amato, Jennifer D Hintzsche, Keith Wells, Allison Applegate, Nicholas T Gorden, Karl D Lewis

Cancers (Basel)· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis